BioVie Inc. Class A BIVI 深 滬
已收盤 02-06 16:00:00 美东时间
1.13
+0.070
+6.60%
華盛通- 最 高1.18
- 今 開1.105
- 成交量 19.47万股
- 最 低 1.08
- 昨 收 1.06
- 總市值 852.06万
- 52周最高 18.60
- 市盈率 靜 --
- 換手率 2.58%
- 52周最低 1.06
- 委 比 -22.77%
- 總股本 754.03万
- 歷史最高 4609.80
- 量 比 1.44
- 振 幅 9.43%
- 歷史最低 1.06
- 每 手 1
- 風險率 4.95%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BioVie Completes Enrollment Of 60 Patients In Phase 2 SUNRISE-PD Clinical Trial Evaluating Bezisterim On Motor And Non-Motor Symptoms In Individuals With Early-Stage PD
- Patient-centric trial aiming to evaluate whether bezisterim can help delay disease progression reaches enrollment milestone -- Topline Results from the SUNRISE-PD Trial Expected in 1H 2026 -CARSON CITY, Nev., Jan. 08,
01-08 21:12
BioVie Q1 EPS $(0.98) Misses $(0.79) Estimate
BioVie (NASDAQ:BIVI) reported quarterly losses of $(0.98) per share which missed the analyst consensus estimate of $(0.79) by 24.05 percent. This is a 86 percent increase over losses of $(7.00) per share from the same
2025-11-11 06:43
BioVie to Host Live Investor Webinar and Q&A on Oct. 8
BioVie Inc. will host an investor webinar on Oct. 8, 2025, to discuss its drug candidate bezisterim, targeting inflammation and insulin resistance in Alzheimer’s, Parkinson’s, and long COVID. CEO Cuong Do will also update on BIV201, a late-stage orphan drug for refractory ascites. With supportive safety data, BioVie is advancing toward key milestones and exploring partnerships. A live Q&A session will follow. Registration is available via the pro...
2025-09-26 12:00
BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes
BioVie Inc. is currently enrolling patients for its Phase 2 ADDRESS-LC trial, focusing on Long COVID-related fatigue and cognitive impairment. The trial evaluates the efficacy of bezisterim, an anti-inflammatory agent, in a randomized, double-blind, placebo-controlled study. Over 400 million individuals globally have been affected by Long COVID, with no FDA-approved treatments available. The study, funded by the U.S. Department of Defense, aims t...
2025-08-13 20:05
Why Expedia Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Shares of Expedia Group, Inc. (NASDAQ:EXPE) rose sharply in pre-market trading ...
2025-08-08 17:14
BioVie stock dips on pricing $12M securities offering
BioVie (NASDAQ:BIVI) has priced a public offering of 6 million units at $2.00 per unit, raising approximately $12 million in gross proceeds. Each unit includes one share of common stock and one warran...
2025-08-08 14:56
BioVie Inc. Announces Pricing of $12 Million Public Offering
BioVie Inc. (NASDAQ: BIVI) announced the pricing of its underwritten public offering of 6 million units at $2.00 per unit, with each unit including one share of common stock and one warrant. The company expects gross proceeds of approximately $12 million before underwriting discounts and expenses. The warrants, exercisable at $2.50 per share, will expire in five years and commence trading on August 8, 2025. Proceeds will be used for working capit...
2025-08-08 00:43
BioVie Expands Board Amid Drug Development Momentum
The latest update is out from BioVie ( ($BIVI) ). On July 17, 2025, BioVie Inc....
2025-07-24 05:27
BioVie Appoints Industry Veterans Amy Chappell, MD, FAAN, and Kameel Farag to Board of Directors
BioVie Inc. has appointed Amy S. Chappell, MD, and Kameel D. Farag to its Board of Directors, bringing significant expertise in neuroscience drug development and financial growth. Dr. Chappell, a seasoned neurologist with extensive experience in CNS drug approvals, joins from Solaxa Inc. Mr. Farag, a financial leader with a track record in scaling biotech companies, previously led Aspen Neuroscience. Their expertise will support BioVie’s Phase 2 ...
2025-07-22 12:00
BioVie Announces Data Highlighting Bezisterim’s Potential to Slow or Reverse Biological Aging and Neurodegeneration Featured as a Keynote Talk at the 7th World Aging and Rejuvenation Conference
BioVie Inc. presented findings at the World Aging and Rejuvenation Conference (ARC-2025) in Vienna, highlighting the potential of its drug candidate, bezisterim, in addressing aging and neurodegeneration through anti-inflammatory epigenetic mechanisms. Data from the Phase 3 NM101 study indicated that bezisterim may slow biological aging by 3.16 to 4.24 years, based on five epigenetic clocks, and improved metabolic and inflammatory biomarkers in p...
2025-07-09 12:00
